BioCentury | Sep 29, 2014
Company News

MedGenesis, Pfizer deal

...develop potential treatments for Parkinson's disease. The technologies are in proof-of-concept testing for the indication. MedGenesis...
...undisclosed milestones and royalties. The companies declined to disclose further terms. PharmaVentures Ltd. advised MedGenesis. MedGenesis Therapeutix Inc....
BioCentury | Jan 16, 2012
Financial News

MedGenesis completes venture financing

MedGenesis Therapeutix Inc. , Victoria, B.C. Business: Neurology, Cancer Date completed: 1/10/12 Type: Venture financing Raised: $5 million WIR Staff cancer Neurology...
BioCentury | Dec 13, 2010
Strategy

Unwinding Biovail's Deals

...returned $40M up front; up to $90M in milestones; 10-25% royalties; no termination fee Jan-10 MedGenesis Therapeutix Inc....
BioCentury | Nov 22, 2010
Company News

MedGenesis, Valeant Pharmaceuticals deal

...preclinical candidate because it did not fit with the merged company's strategic and financial focus. MedGenesis...
...will receive $5 million in cash from Valeant to accelerate development of GDNF in PD. MedGenesis...
...MedGenesis has exclusive, worldwide rights to the compound from Amgen Inc. (NASDAQ:AMGN, Thousand Oaks, Calif.). MedGenesis Therapeutix Inc....
BioCentury | Nov 8, 2010
Clinical News

Glial derived neurotrophic factor: Development discontinued

...did not fit with the merged company's strategic and financial focus (see BioCentury, Oct. 4). MedGenesis...
...PD and other CNS indications (see BioCentury, Jan. 25). Amgen Inc. (NASDAQ:AMGN), Thousand Oaks, Calif. MedGenesis Therapeutix Inc....
BioCentury | Nov 5, 2010
Top Story

Valeant continues to carve up Biovail

...this year, did not fit with the merged company's strategic and financial focus. In January, MedGenesis Therapeutix Inc....
BioCentury | Aug 30, 2010
Company News

Jennerex management update

...Business: Cancer Hired: Lara Longpre as COO, formerly SVP of clinical and corporate affairs at MedGenesis Therapeutix Inc. WIR...
BioCentury | Jan 25, 2010
Company News

MedGenesis, Amgen, Biovail deal

...Amgen granted MedGenesis exclusive, worldwide rights to glial cell-derived neurotrophic factor (GDNF) protein. Amgen received a...
...to glial cell-derived neurotrophic factor (GDNF) protein. Amgen received a high single-digit percentage stake in MedGenesis...
...undisclosed upfront payment. Amgen also is eligible for milestones and royalties. At the same time, MedGenesis...
Items per page:
1 - 8 of 8
BioCentury | Sep 29, 2014
Company News

MedGenesis, Pfizer deal

...develop potential treatments for Parkinson's disease. The technologies are in proof-of-concept testing for the indication. MedGenesis...
...undisclosed milestones and royalties. The companies declined to disclose further terms. PharmaVentures Ltd. advised MedGenesis. MedGenesis Therapeutix Inc....
BioCentury | Jan 16, 2012
Financial News

MedGenesis completes venture financing

MedGenesis Therapeutix Inc. , Victoria, B.C. Business: Neurology, Cancer Date completed: 1/10/12 Type: Venture financing Raised: $5 million WIR Staff cancer Neurology...
BioCentury | Dec 13, 2010
Strategy

Unwinding Biovail's Deals

...returned $40M up front; up to $90M in milestones; 10-25% royalties; no termination fee Jan-10 MedGenesis Therapeutix Inc....
BioCentury | Nov 22, 2010
Company News

MedGenesis, Valeant Pharmaceuticals deal

...preclinical candidate because it did not fit with the merged company's strategic and financial focus. MedGenesis...
...will receive $5 million in cash from Valeant to accelerate development of GDNF in PD. MedGenesis...
...MedGenesis has exclusive, worldwide rights to the compound from Amgen Inc. (NASDAQ:AMGN, Thousand Oaks, Calif.). MedGenesis Therapeutix Inc....
BioCentury | Nov 8, 2010
Clinical News

Glial derived neurotrophic factor: Development discontinued

...did not fit with the merged company's strategic and financial focus (see BioCentury, Oct. 4). MedGenesis...
...PD and other CNS indications (see BioCentury, Jan. 25). Amgen Inc. (NASDAQ:AMGN), Thousand Oaks, Calif. MedGenesis Therapeutix Inc....
BioCentury | Nov 5, 2010
Top Story

Valeant continues to carve up Biovail

...this year, did not fit with the merged company's strategic and financial focus. In January, MedGenesis Therapeutix Inc....
BioCentury | Aug 30, 2010
Company News

Jennerex management update

...Business: Cancer Hired: Lara Longpre as COO, formerly SVP of clinical and corporate affairs at MedGenesis Therapeutix Inc. WIR...
BioCentury | Jan 25, 2010
Company News

MedGenesis, Amgen, Biovail deal

...Amgen granted MedGenesis exclusive, worldwide rights to glial cell-derived neurotrophic factor (GDNF) protein. Amgen received a...
...to glial cell-derived neurotrophic factor (GDNF) protein. Amgen received a high single-digit percentage stake in MedGenesis...
...undisclosed upfront payment. Amgen also is eligible for milestones and royalties. At the same time, MedGenesis...
Items per page:
1 - 8 of 8